TABLE 5.
Vaccine potential of various eukaryotic plasmids that express flavivirus prM and E proteinsa
| Virus | In vitro secretion of EPs | Immunization
|
Protection from virus challenge | Reference | ||
|---|---|---|---|---|---|---|
| Dosage | Route/method | Neutralizing antibodyb | ||||
| JE | Yes | 25–100 μg × 1 | i.m./needle | Yes (1:20–1:16090%) | 100% | This report |
| ND | 100 μg × 2 | i.m./needle | No | Partial | 30 | |
| ND | 10–100 μg × 2 | i.m. or i.d./needle | Yes (1:10–1:2090%) | 100% | 24 | |
| MVE | Yes | 100 μg × 4 | i.m./needle | ND | Partial | 4 |
| Yes | 1–2 μg × 2–4 | i.d./gene gun | Yes (80–32050%) | 100% | 4 | |
| SLE | ND | 100 μg × 2 | i.m./needle | No | Partial | 38 |
| CEE | ND | 1 μg × 1–2 | i.d./gene gun | Yes (1:100–1:1,60080%) | 100% | 49 |
| RSSE | ND | 1 μg × 1–2 | i.d./gene gun | ND | 100% | 49 |
| DEN2 | ND | 200 μg × 3 | i.d./needle | Yes (1:10–1:32050%) | None | 17 |
a
MVE, Murray Valley encephalitis; CEE, Central European encephalitis; RSSE, Russian spring-summer encephalitis; i.d., intradermal; ND, not done.
b
Plaque reduction neutralization titer followed by percentage reduction endpoint used in the test.